Mingwei Chen

Dr. Mingwei Chen


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Cancer Letters
Verified
Journal Article
Closed access
PSPuyu Shi
Puyu Shi
YOYou-Take Oh
You-Take Oh
GZGuojing Zhang
Guojing Zhang
WYWeilong Yao
Weilong Yao
PYPing Yue
Ping Yue
Shi-Yong SunShi-Yong Sun
Shi-Yong Sun

31 October 2017 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PSPuyu Shi
Puyu Shi
YOYou-Take Oh
You-Take Oh
LDLiang Deng
Liang Deng
GZGuojing Zhang
Guojing Zhang
GQGuoqing Qian
Guoqing Qian
Shi-Yong SunShi-Yong Sun
Shi-Yong Sun
Purpose: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO), an approved third-generation EGFR inhibitor, in EGFR-mutant non–small cell lung cancer (NSCLC) cells and particularly for the subsequent development of acquired resistance are unclear and thus are the focus of this study. Experimental Design: AZD9219-resistant cell lines were established by exposing sensitive cell lines to AZD9291. Protein alterations were detected with Western blotting. Apoptosis was measured with annexin V/flow cytometry. Growth-inhibitory effects of tested drugs were evaluated in vitro with cell number estimation and colony formation assay and in vivo with mouse xenograft models. Protein degradation was determined by comparing protein half-lives and inhibiting proteasome. Gene knockdown were achieved with siRNA or shRNA. Results: AZD9291 potently induced apoptosis in EGFR-mutant NSCLC cell lines, in which ERK phosphorylation was suppressed accompanied with Bim elevation and Mcl-1 reduction likely due to enhanced Mcl-1 degradation and increased Bim stability. Blocking Bim elevation by gene knockdown or enforcing Mcl-1 expression attenuated or abolished AZD9291-induced apoptosis. Moreover, AZD9291 lost its ability to modulate Bim and Mcl-1 levels in AZD9291-resistant cell lines. The combination of a MEK inhibitor with AZD9291 restores the sensitivity of AZD9291-resistant cells including those with C797S mutation to undergo apoptosis and growth regression in vitro and in vivo. Conclusions: Modulation of MEK/ERK-dependent Bim and Mcl-1 degradation critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291. Clin Cancer Res; 23(21); 6567–79. ©2017 AACR.

22 November 2013 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
HRHui Ren
Hui Ren
JKJunghui Koo
Junghui Koo
BGBaoxiang Guan
Baoxiang Guan
PYPing Yue
Ping Yue
Xingming DengXingming Deng
Xingming Deng
Shi-Yong SunShi-Yong Sun
Shi-Yong Sun
Background: The novel Akt inhibitor, API-1, induces apoptosis through undefined mechanisms. The current study focuses on revealing the mechanisms by which API-1 induces apoptosis. Results: API-1 rapidly and potently reduced the levels of Mcl-1 primarily in API-1-senstive lung cancer cell lines. Ectopic expression of Mcl-1 protected cells from induction of apoptosis by API-1. API-1 treatment decreased the half-life of Mcl-1, whereas inhibition of the proteasome with MG132 rescued Mcl-1 reduction induced by API-1. API-1 decreased Mcl-1 levels accompanied with a rapid increase in Mcl-1 phosphorylation (S159/T163). Moreover, inhibition of GSK3 inhibited Mcl-1 phosphorylation and reduction induced by API-1 and antagonized the effect of API-1 on induction of apoptosis. Knockdown of either FBXW7 or β-TrCP alone, both of which are E3 ubiquitin ligases involved in Mcl-1 degradation, only partially rescued Mcl-1 reduction induced by API-1. However, double knockdown of both E3 ubiquitin ligases enhanced the rescue of API-1-induced Mcl-1 reduction. Conclusions: API-1 induces GSK3-dependent, β-TrCP- and FBXW7-mediated Mcl-1 degradation, resulting in induction of apoptosis.

1 March 2019
Verified
Journal Article
Open access
PDF file
TYTian Yang
Tian Yang
HLHong Li
Hong Li
TCTianjun Chen
Tianjun Chen
HRHui Ren
Hui Ren
PSPuyu Shi
Puyu Shi
MCMingwei Chen
Mingwei Chen
Tian Yang, Hong Li, Tianjun Chen, Hui Ren, Puyu Shi, and Mingwei Chen. Mol. Cells 2019;42:270-83. https://doi.org/10.14348/molcells.2019.2364

1 December 2012 in Cancer Letters
Verified
Journal Article
Closed access
HRHui Ren
Hui Ren
MCMingwei Chen
Mingwei Chen
PYPing Yue
Ping Yue
HTHui Tao
Hui Tao
TOTaofeek Owonikoko
Taofeek Owonikoko
Shi-Yong SunShi-Yong Sun
Shi-Yong Sun

10 May 2019 in Clinical Proteomics
Verified
Journal Article
Open access
PDF file
YLYiqian Liang
Yiqian Liang
PHPeng Han
Peng Han
TWTing Wang
Ting Wang
HRHui Ren
Hui Ren
LGLei Gao
Lei Gao
MCMingwei Chen
Mingwei Chen
Lung cancer is the leading cause of cancer death in China and around the world. Early detection is key to improving the survival rate of non-small cell lung cancer (NSCLC). Alteration in glycosylation has been observed in cancers, and glycans can be a source for the development of new biomarkers for NSCLC. In this glycan biomarker discovery study, we measured serum N- and O-glycan profiles in NSCLC patients with different stages and healthy controls by performing lectin microarray analysis. The alterations of serum glycopatterns were compared between NSCLC patients and controls, and the stage-related changes in serum glycosylation were evaluated. There were 18 lectins (e.g., AAL, Jacalin, GSL-I and DBA) to give significantly alterations of serum glycopatterns in lung adenocarcinoma compared with control group. Meanwhile, 16 lectins (e.g., Jacalin, HHL, and PHA-E+L) exhibited significantly alterations of serum glycopatterns in squamous cell carcinoma (SCC) compared with control group. Importantly, most of the lectins showing altered signals exhibited significantly increased or decreased NFIs in patients with early stage adenocarcinoma and SCC. The serum glycan profiles were significantly different between NSCLC and healthy control, and most of the glycosylation changes had occurred at early stage. Further evaluation is needed to examine the diagnostic value of the glycan markers identified in this study.